JP2019167381A5 - - Google Patents

Download PDF

Info

Publication number
JP2019167381A5
JP2019167381A5 JP2019111673A JP2019111673A JP2019167381A5 JP 2019167381 A5 JP2019167381 A5 JP 2019167381A5 JP 2019111673 A JP2019111673 A JP 2019111673A JP 2019111673 A JP2019111673 A JP 2019111673A JP 2019167381 A5 JP2019167381 A5 JP 2019167381A5
Authority
JP
Japan
Prior art keywords
cns
cell
progenitor
ikaros
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019111673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019167381A (ja
JP6945591B2 (ja
Filing date
Publication date
Priority claimed from JP2016570924A external-priority patent/JP6870988B2/ja
Application filed filed Critical
Publication of JP2019167381A publication Critical patent/JP2019167381A/ja
Publication of JP2019167381A5 publication Critical patent/JP2019167381A5/ja
Priority to JP2021116952A priority Critical patent/JP2021178837A/ja
Application granted granted Critical
Publication of JP6945591B2 publication Critical patent/JP6945591B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019111673A 2014-02-24 2019-06-17 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法 Active JP6945591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021116952A JP2021178837A (ja) 2014-02-24 2021-07-15 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201461943857P 2014-02-24 2014-02-24
US61/943,857 2014-02-24
US201462035936P 2014-08-11 2014-08-11
US62/035,936 2014-08-11
US201462049260P 2014-09-11 2014-09-11
US201462049191P 2014-09-11 2014-09-11
US62/049,260 2014-09-11
US62/049,191 2014-09-11
US201462062641P 2014-10-10 2014-10-10
US62/062,641 2014-10-10
US201562109542P 2015-01-29 2015-01-29
US62/109,542 2015-01-29
JP2016570924A JP6870988B2 (ja) 2014-02-24 2015-02-23 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016570924A Division JP6870988B2 (ja) 2014-02-24 2015-02-23 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021116952A Division JP2021178837A (ja) 2014-02-24 2021-07-15 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法

Publications (3)

Publication Number Publication Date
JP2019167381A JP2019167381A (ja) 2019-10-03
JP2019167381A5 true JP2019167381A5 (https=) 2020-01-30
JP6945591B2 JP6945591B2 (ja) 2021-10-06

Family

ID=53879089

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016570924A Active JP6870988B2 (ja) 2014-02-24 2015-02-23 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
JP2019111673A Active JP6945591B2 (ja) 2014-02-24 2019-06-17 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
JP2021116952A Pending JP2021178837A (ja) 2014-02-24 2021-07-15 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016570924A Active JP6870988B2 (ja) 2014-02-24 2015-02-23 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021116952A Pending JP2021178837A (ja) 2014-02-24 2021-07-15 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法

Country Status (4)

Country Link
US (1) US10272117B2 (https=)
EP (2) EP3450571B1 (https=)
JP (3) JP6870988B2 (https=)
WO (1) WO2015127351A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2014240083C1 (en) 2013-03-15 2019-10-24 Celgene Corporation Modified T lymphocytes
JP6653120B2 (ja) * 2014-10-31 2020-02-26 千寿製薬株式会社 Ｉｋａｒｏｓ阻害に基づく抗炎症薬
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
US11963520B2 (en) 2016-01-19 2024-04-23 Celgene Corporation Transgenic mouse expressing human cereblon
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
WO2018075820A2 (en) * 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
WO2018144832A1 (en) 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
KR102050774B1 (ko) * 2017-08-14 2019-12-02 충남대학교산학협력단 세레브론 단백질 또는 이를 코딩하는 유전자를 포함하는 근육 손상으로 유도된 근육 질환의 예방 또는 치료용 조성물
JP7585034B2 (ja) * 2017-10-18 2024-11-18 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
CN108753833B (zh) * 2018-05-28 2021-12-03 上海海洋大学 斑马鱼notch3基因突变体的制备方法
AU2021250052A1 (en) 2020-03-31 2022-11-03 Sky Pharma Co.,Ltd. Method for screening for, method for producing, and method for designing drug active ingredients
WO2021207387A1 (en) * 2020-04-08 2021-10-14 Rumi Scientific Holdings, Inc. Use of bromodomain inhibitors for treatment of huntington's disease

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
ES2154637T3 (es) 1991-05-14 2001-04-16 Univ Connecticut Aportacion de genes dirigidos que codifican proteinas inmunogenicas.
ES2149774T3 (es) 1991-06-05 2000-11-16 Univ Connecticut Aportacion dirigida de genes que codifican proteinas secretoras.
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
US5824770A (en) * 1992-09-14 1998-10-20 The General Hospital Corporation Ikaros polypeptides
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
JP2002315576A (ja) 2001-04-23 2002-10-29 Inst Of Physical & Chemical Res 遺伝子発現調節方法
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US20050182097A1 (en) 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
US20100021437A1 (en) * 2008-04-07 2010-01-28 The McLean Hospital Corporation Whitehead Institute for Biomedical Research Neural stem cells derived from induced pluripotent stem cells
US9034319B2 (en) * 2008-05-26 2015-05-19 Yeda Research And Development Co. Ltd. Methods of treating cancer of the central nervous system
EP2436387B1 (en) * 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
EP2726821A2 (en) * 2011-12-30 2014-05-07 Convotherm Elektrogeräte GmbH Continuously monitored core temperature sensor and method
WO2014028445A2 (en) * 2012-08-14 2014-02-20 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
JP2016519672A (ja) * 2013-03-15 2016-07-07 ジェネンテック， インコーポレイテッド ブロモドメイン含有タンパク質ｂｒｄ７およびｂｒｄ９の阻害によるｔｈ２媒介性疾患の治療

Similar Documents

Publication Publication Date Title
JP2019167381A5 (https=)
JP2017511814A5 (https=)
Seib et al. Neurogenesis in the normal ageing hippocampus: a mini-review
Corti et al. Direct reprogramming of human astrocytes into neural stem cells and neurons
JP5816644B2 (ja) ヒト胚性幹細胞から、高収率で、神経前駆細胞、神経細胞及び機能性ドーパミン神経細胞を生成する方法
WO2017084770A1 (en) Microglial microvesicles contained microrna-based methods for the diagnosis, prognosis and treatment monitoring of neurological, neurodegenerative and inflammation-based diseases
JP2017503849A5 (https=)
de Mara et al. Chondrogenesis from umbilical cord blood cells stimulated with BMP-2 and BMP-6
JP7298858B2 (ja) 髄核細胞マスターレギュレーター転写因子を含む分化誘導剤、誘導髄核細胞の製造方法、および誘導髄核細胞の用途
JP2020513823A5 (https=)
MY168084A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
JP2022503604A (ja) 合成メッセンジャーｒｎａを用いて尿細胞を神経幹細胞へ直接逆分化する方法
Liu et al. The Rho kinase inhibitor Y-27632 facilitates the differentiation of bone marrow mesenchymal stem cells
CN110997706B (zh) 通过利用地标转录因子的干细胞分化诱导神经祖细胞、寡树突细胞祖细胞及寡树突细胞
Mortezaee et al. Retinoic acid as the stimulating factor for differentiation of Wharton's Jelly-Mesenchymal stem cells into hepatocyte-like cells
Payne et al. The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis
JP6290876B2 (ja) 神経前駆細胞を用いた細胞治療における移植補助剤
Gosselin Epigenomic and transcriptional determinants of microglial cell identity
Okano et al. Isolation and transplantation of dopaminergic neurons and neural stem cells
Evans et al. Parkinson's disease and microRNAs-Lessons from model organisms and human studies
Ghasemi et al. Neuroprotective effect of diosgenin in 6-hydroxydopamine-induced model of Parkinsonâ s disease in the rat
KR101971558B1 (ko) Lin28의 발현을 이용한 재생능 및 분화능이 우수한 줄기세포의 제조방법
Nawal A systems biology perspective of stem cell differentiation into microglia
US20220396772A1 (en) Materials and methods for generating therapeutic mesenchymal stem cells
JP5784296B2 (ja) 神経細胞の製造方法及び神経細胞分化促進剤